Researchers at the University of Pittsburgh have developed 2nd generation griffithsin mutants with enhanced stability and solubility. Griffithsin is a potent antiviral protein effective against HIV and other viruses. The modified griffithsin polypeptides exhibit reduced methionine oxidation, increased shelf-life, and improved solubility, making them more suitable for pharmaceutical development and extending their usable storage times. These advancements could significantly impact the development of antiviral therapies and improve the efficacy of griffithsin-based treatments.